

Magle Group Announces Revised Publication Date for Q4 2024 and Full-Year 2024 Reports Due to Ongoing Consolidation Process

Malmö, Sweden – Magle Group announces a revised publication date for its Q4 2024 and Full-Year 2024 financial report, and its 2024 Annual Report. The Q4 2024 and Full-Year 2024 financial report, originally scheduled for release on 26 February 2025, will now be published on 27 March 2025. The 2024 Annual Report will be published on 28 April 2025.

The revised timeline is due to the ongoing auditing and consolidation process following the mergers with Amniotics AB and PK Chemicals A/S, which were finalised in the latter part of 2024. As these entities are integrated into Magle Group's financial structure, additional time is required to ensure the highest level of accuracy and transparency in reporting.

Aaron Wong, CFO of Magle Group, commented, "With the successful integration of Amniotics AB and PK Chemicals A/S into Magle Group, we are in a transformative phase of growth. Given the complexity of consolidating these businesses, our audit process requires additional time. We remain committed to providing a clear and accurate financial picture to our stakeholders and appreciate the patience and understanding of our investors as we complete this important process."

Magle Group remains confident in the long-term strategic value of these acquisitions and the opportunities they bring for the company's future growth.

The company will provide further updates as needed.

For enquiries, please contact:

Magle Group

Justin Pierce, CEO

Email: justin.pierce@maglechemoswed.com

Telephone: +46 (0) 70 593 58 21

About Magle Group

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group's medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com, www.maglegroup.com, www.maglepharmaceut.com and www.maglebiopolymers.com.

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

[Magle Group Announces Revised Publication Date for Q4 2024 and Full-Year 2024 Reports Due to Ongoing Consolidation Process](#)